CLBT
Cellebrite DI
11.10$
-0.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +10.5% | -3.7% | +6.8% | +11.6% | +2.1% | -1.4% | +5.3% | +11.3% | +2.2% | -0.4% | +2.2% | – | |
| – | +15.8% | -11.1% | +22.6% | -5.0% | +14.1% | -0.8% | +1.1% | +14.9% | -3.1% | +13.9% | +12.4% | – | |
| – | +9.5% | -2.3% | +4.1% | +15.1% | +0.0% | -1.5% | +6.2% | +10.6% | +3.2% | -3.0% | +0.0% | – | |
| – | +6.4% | +6.6% | +2.1% | +9.4% | -1.3% | +6.6% | +4.9% | -1.7% | +6.2% | +20.1% | +0.2% | – | |
| – | +12.0% | +0.5% | -7.3% | +23.8% | +7.5% | -19.4% | +18.2% | +42.6% | +0.5% | -11.2% | +256.7% | – | |
| – | +9.1% | +6.3% | -0.2% | +7.5% | +5.2% | +2.8% | +4.4% | +6.8% | +1.8% | +9.6% | +1.6% | – | |
| – | +11.3% | -38.3% | +35.0% | +55.7% | -19.1% | -22.0% | +17.5% | +31.7% | +9.6% | -56.2% | -16.4% | – | |
| – | +312.4% | +187.4% | -56.1% | +549.2% | -99.4% | – | – | – | – | – | – | – | |
| – | -280.2% | – | – | – | – | -2.9% | +7.6% | +16.8% | +8.2% | -48.1% | -17.9% | – | |
| – | +559.6% | -11.3% | -12.1% | +42.3% | -75.4% | +207.0% | -31.8% | +211.7% | +22.2% | -46.2% | +78.6% | – | |
| – | -325.3% | – | – | – | – | -9.7% | +11.9% | +3.7% | +5.3% | -48.6% | -41.8% | – | |
| – | -674.1% | – | +26.3% | +46.5% | -1,524.8% | – | +39.0% | -11.6% | +83.3% | -58.3% | -19.9% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.